Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014 Candidate	Dec. 31, 2011	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of VDA drug candidates tested	2
Accumulated earnings (deficit)	$ (241,138,000)		$ (238,508,000)
Cash	24,735,000		7,005,000	4,562,000	4,946,000
Period of inspection of product	30 days
Percentage payment on gross margin of distributor's sales	20.00%
Cost-of-goods-sold		$ 0